The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letter to the EditorFull Access

Mood Stabilizer Combinations for Bipolar Disorder

Published Online:https://doi.org/10.1176/ajp.156.6.980a

To the Editor: The article by Marlene P. Freeman, M.D., and Andrew L. Stoll, M.D., on combinations of mood stabilizers for treatment of bipolar disorder (1) noted the potentially dangerous interaction of lamotrigine with valproate. Unfortunately, the authors failed to mention that the risk of severe and at times fatal rashes associated with lamotrigine is much higher in the pediatric population. Readers should have been reminded of the one in 50 to one in 100 chance of life-threatening rashes associated with the use of lamotrigine in children and adolescents under 16 years. The product information monograph bears a boxed warning emphasizing that lamotrigine is not approved for use in patients below the age of 16 years.

References

1. Freeman MP, Stoll AL: Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998; 155:12–21LinkGoogle Scholar